Your browser doesn't support javascript.
loading
Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma.
Machiela, Mitchell J; Hofmann, Jonathan N; Carreras-Torres, Robert; Brown, Kevin M; Johansson, Mattias; Wang, Zhaoming; Foll, Matthieu; Li, Peng; Rothman, Nathaniel; Savage, Sharon A; Gaborieau, Valerie; McKay, James D; Ye, Yuanqing; Henrion, Marc; Bruinsma, Fiona; Jordan, Susan; Severi, Gianluca; Hveem, Kristian; Vatten, Lars J; Fletcher, Tony; Koppova, Kvetoslava; Larsson, Susanna C; Wolk, Alicja; Banks, Rosamonde E; Selby, Peter J; Easton, Douglas F; Pharoah, Paul; Andreotti, Gabriella; Freeman, Laura E Beane; Koutros, Stella; Albanes, Demetrius; Mannisto, Satu; Weinstein, Stephanie; Clark, Peter E; Edwards, Todd E; Lipworth, Loren; Gapstur, Susan M; Stevens, Victoria L; Carol, Hallie; Freedman, Matthew L; Pomerantz, Mark M; Cho, Eunyoung; Kraft, Peter; Preston, Mark A; Wilson, Kathryn M; Gaziano, J Michael; Sesso, Howard S; Black, Amanda; Freedman, Neal D; Huang, Wen-Yi.
Afiliación
  • Machiela MJ; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Hofmann JN; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Carreras-Torres R; International Agency for Research on Cancer (IARC), Lyon, France.
  • Brown KM; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Johansson M; International Agency for Research on Cancer (IARC), Lyon, France.
  • Wang Z; St. Jude Children's Research Hospital, Memphis, TN, USA.
  • Foll M; International Agency for Research on Cancer (IARC), Lyon, France.
  • Li P; International Agency for Research on Cancer (IARC), Lyon, France.
  • Rothman N; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Savage SA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Gaborieau V; International Agency for Research on Cancer (IARC), Lyon, France.
  • McKay JD; International Agency for Research on Cancer (IARC), Lyon, France.
  • Ye Y; Department of Epidemiology, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Henrion M; Icahn School of Medicine, New York, NY, USA.
  • Bruinsma F; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Australia.
  • Jordan S; QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia; School of Public Health, The University of Queensland, Brisbane, Australia.
  • Severi G; Cancer Epidemiology and Intelligence Division, Cancer Council Victoria, Melbourne, Australia; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Australia; Human Genetics Foundation (HuGeF), Torino, Italy; Centre de Rech
  • Hveem K; HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Sweden.
  • Vatten LJ; Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Fletcher T; London School of Hygiene and Tropical Medicine, University of London, London, UK.
  • Koppova K; Regional Authority of Public Health in Banska Bystrica, Banska Bystrica, Slovakia.
  • Larsson SC; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Wolk A; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Banks RE; Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds, UK.
  • Selby PJ; Leeds Institute of Cancer and Pathology, University of Leeds, Cancer Research Building, St James's University Hospital, Leeds, UK.
  • Easton DF; Department of Oncology, and Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Pharoah P; Department of Oncology, and Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Andreotti G; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Freeman LEB; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Koutros S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Albanes D; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Mannisto S; National Institute for Health and Welfare, Helsinki, Finland.
  • Weinstein S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Clark PE; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Edwards TE; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Lipworth L; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
  • Gapstur SM; American Cancer Society, Atlanta, GA, USA.
  • Stevens VL; American Cancer Society, Atlanta, GA, USA.
  • Carol H; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Freedman ML; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Pomerantz MM; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Cho E; Brown University, Providence, RI, USA.
  • Kraft P; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Preston MA; Brigham and Women's Hospital, Boston, MA, USA.
  • Wilson KM; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Gaziano JM; Brigham and Women's Hospital, Boston, MA, USA; Veterans Administration, Boston, MA, USA.
  • Sesso HS; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
  • Black A; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Freedman ND; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
  • Huang WY; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department Health and Human Services, Bethesda, MS, USA.
Eur Urol ; 72(5): 747-754, 2017 11.
Article en En | MEDLINE | ID: mdl-28797570
BACKGROUND: Relative telomere length in peripheral blood leukocytes has been evaluated as a potential biomarker for renal cell carcinoma (RCC) risk in several studies, with conflicting findings. OBJECTIVE: We performed an analysis of genetic variants associated with leukocyte telomere length to assess the relationship between telomere length and RCC risk using Mendelian randomization, an approach unaffected by biases from temporal variability and reverse causation that might have affected earlier investigations. DESIGN, SETTING, AND PARTICIPANTS: Genotypes from nine telomere length-associated variants for 10 784 cases and 20 406 cancer-free controls from six genome-wide association studies (GWAS) of RCC were aggregated into a weighted genetic risk score (GRS) predictive of leukocyte telomere length. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) relating the GRS and RCC risk were computed in individual GWAS datasets and combined by meta-analysis. RESULTS AND LIMITATIONS: Longer genetically inferred telomere length was associated with an increased risk of RCC (OR=2.07 per predicted kilobase increase, 95% confidence interval [CI]:=1.70-2.53, p<0.0001). As a sensitivity analysis, we excluded two telomere length variants in linkage disequilibrium (R2>0.5) with GWAS-identified RCC risk variants (rs10936599 and rs9420907) from the telomere length GRS; despite this exclusion, a statistically significant association between the GRS and RCC risk persisted (OR=1.73, 95% CI=1.36-2.21, p<0.0001). Exploratory analyses for individual histologic subtypes suggested comparable associations with the telomere length GRS for clear cell (N=5573, OR=1.93, 95% CI=1.50-2.49, p<0.0001), papillary (N=573, OR=1.96, 95% CI=1.01-3.81, p=0.046), and chromophobe RCC (N=203, OR=2.37, 95% CI=0.78-7.17, p=0.13). CONCLUSIONS: Our investigation adds to the growing body of evidence indicating some aspect of longer telomere length is important for RCC risk. PATIENT SUMMARY: Telomeres are segments of DNA at chromosome ends that maintain chromosomal stability. Our study investigated the relationship between genetic variants associated with telomere length and renal cell carcinoma risk. We found evidence suggesting individuals with inherited predisposition to longer telomere length are at increased risk of developing renal cell carcinoma.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Telómero / Polimorfismo de Nucleótido Simple / Homeostasis del Telómero / Neoplasias Renales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Eur Urol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Telómero / Polimorfismo de Nucleótido Simple / Homeostasis del Telómero / Neoplasias Renales Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Eur Urol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos